Freedom Capital Markets Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $73

Benzinga Newsdesk www.benzinga.com Neutral 66.6%

Neg 0% Neu 66.6% Pos 0%

Freedom Capital Markets analyst Keith Hinton initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $73.